A biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH).

Madrigal Pharmaceuticals

Madrigal (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis. For more information, visit www.madrigalpharma.com. 

Hercules Capital

Bay City Capital

Join us at Digestive Disease Week® (DDW) for an engaging Product Theater discussing a new option available for #NASH / #MASH patients with liver fibrosis. #DDW2024​

Watch how a community engages with a realistic liver model at our recent community liver health education and screening event: https://lnkd.in/g9PeyEY2

Liam Swain (recently accepted into medical school) interacts closely wth a very curious group of attendees at our Global Fatty Liver Day event.

Link to video: https://lnkd.in/g9PeyEY2

American Association for the Study of Liver Diseases (AASLD) EASL | The Home of Hepatology European Liver Patients'​ Association - ELPA LPI LIVER PATIENTS INTERNATIONAL Global Liver Institute, Canadian Association for the Study of the Liver, Prof. Shira Zelber Sagi, Jonathan G. Stine, MD MSc, FACP, Manal Abdelmalek, Rachael Sood RN, MSN, NP-C, CDCES, Arizona Liver Health, Naim Alkhouri, MD, FAASLD, Mazen Noureddin, MD, MHSc, Jörn M. Schattenberg, Zobair Younossi, Global NASH Council, Obesity Matters , Paul Brennan, Christopher Kopka, American Diabetes Association, Barcelona Institute for Global Health (ISGlobal), Jeffrey V. Lazarus, Dexcom, Michael Reiner, MBA, Elizabeth Pekas, PhD,  Donna Cryer, Madrigal Pharmaceuticals, Chris Frates, Chris Dadas

We’ll be in Orlando, FL for the American Diabetes Association's 84th Scientific Sessions. Will you? Stop by our e-poster session on #NASH / #MASH between 12:30-1:30 p.m. EDT on Sunday, June 23. Swipe to learn more. #ADA2024 ​

We are proud to sponsor Global Liver Institute's Global #FattyLiverDay, an awareness initiative that prioritizes the lives of those impacted by #NASH / #MASH. Help us increase education by joining the conversation.​

Join us in Venice, Italy for the European Association for the Study of Obesity (EASO)’s 31st European Congress on Obesity. Swipe to learn more about our #NASH / #MASH data presentations. We hope to see you there! #ECO2024

Madrigal is aware of a press release issued by the American Association for the Study of Liver Disease (AASLD) announcing the FDA approval of resmetirom.  While today is the PDUFA date for resmetirom, Madrigal has not received notification from the FDA. AASLD is removing the press release from its website.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

COM:MADRIGALPHARMA

Madrigal Pharmaceuticals

Last Close

317.09

21/11 21:00

Market Cap

6.06B

Beta: -

Volume Today

421.87K

Avg: -

Filings Not Available